Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

A compound of Formula I or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt,

• wherein:
• R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy;
• R12 is hydrogen, C1-C6alkyl, or C1-C6haloalkyl;
• L1 is —(CH2)m— wherein m is an integer from 0 to 12, wherein each CH2 is individually replaced with —O—, —NH(CO)—, or —(CO)—NH—, provided that no two adjacent CH2 groups are replaced;
• L2 is —(CH2)n— wherein n is an integer from 0 to 12, wherein each CH2 is individually replaced with —O—, —NH(CO)—, or —(CO)—NH—, provided that no two adjacent CH2 groups are replaced;
• L3 is —(CH2)p— wherein p is an integer from 0 to 12, wherein each CH2 is individually replaced with —O—, —NH(CO)—, or —(CO)—NH—, provided that no two adjacent CH2 groups are replaced;
• and
• L4 is a C1-C60 linking group, optionally including —O—, —S—, —S(O)—, —S(O)2—, —N(R)—, —C(═O)—, —C(═O)O—, —OC(═O)—, —N(R)C(═O)—, —C(═O)N(R)—, —OC(═O)O—, —N(R)C(═O)O—, or —OC(═O)N(R)—, wherein each R is H or C1-C6 alkyl;
• R13 is a chelating group;
• and
• R14 is a group capable of binding to prostate-specific membrane antigen (PSMA).